[{"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-001", "question": "A 52-year-old male presents with severe chronic watery diarrhea and 15 kg weight loss over 6 months. He has a history of hypertension treated with olmesartan and amlodipine. Celiac serologies (tTG-IgA, EMA) are negative. Upper endoscopy reveals scalloping of duodenal folds; biopsy shows total villous atrophy and increased intraepithelial lymphocytes. HLA-DQ2 and HLA-DQ8 genotyping is negative. A gluten-free diet for 8 weeks yields no clinical improvement. What is the most likely diagnosis?", "options": ["Refractory Celiac Disease Type 1", "Autoimmune Enteropathy", "Olmesartan-associated Enteropathy", "Common Variable Immunodeficiency (CVID)", "Tropical Sprue"], "answer": "C", "answer_index": 2, "explanation": "Olmesartan-associated enteropathy mimics celiac disease histologically (villous atrophy) but occurs in patients without the genetic predisposition for celiac disease (HLA-DQ2/DQ8 negative). The key discriminator is the medication history and lack of response to gluten withdrawal. Refractory celiac disease requires a prior confirmed diagnosis of celiac disease (positive genetics/serology).", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include olmesartan use for hypertension, negative celiac serologies (tTG-IgA, EMA), negative HLA-DQ2/DQ8 genotyping, endoscopic scalloping with biopsy showing total villous atrophy and increased intraepithelial lymphocytes, and no improvement on 8-week gluten-free diet. These findings strongly point to olmesartan-associated enteropathy, which mimics celiac disease histologically but lacks genetic predisposition and responds poorly to gluten withdrawal. Main logical issue(s): None; the stem provides sufficient discriminating details (medication history, negative markers, lack of GFD response) to identify C as the unique best without contradictions or underspecification. Alternatives are inferior: A (Refractory Celiac Disease Type 1) requires prior celiac confirmation with positive serology/genetics, absent here; B (Autoimmune Enteropathy) typically involves autoantibodies or systemic autoimmunity, not mentioned; D (CVID) often presents with infections and hypogammaglobulinemia, unspecified; E (Tropical Sprue) implies travel to endemic areas, not indicated. Main medical accuracy issue(s): None; aligns with established knowledge that olmesartan can cause sprue-like enteropathy mimicking celiac, per guidelines and literature (e.g., FDA warnings). Item is clinically realistic and board-relevant. Minimal fix: No fix required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include olmesartan use for hypertension, negative celiac serologies (tTG-IgA, EMA), negative HLA-DQ2/DQ8 genotyping, endoscopic scalloping with biopsy showing total villous atrophy and increased intraepithelial lymphocytes, and no improvement on 8-week gluten-free diet. These findings strongly point to olmesartan-associated enteropathy, which mimics celiac disease histologically but lacks genetic predisposition and responds poorly to gluten withdrawal. Main logical issue(s): None; the stem provides sufficient discriminating details (medication history, negative markers, lack of GFD response) to identify C as the unique best without contradictions or underspecification. Alternatives are inferior: A (Refractory Celiac Disease Type 1) requires prior celiac confirmation with positive serology/genetics, absent here; B (Autoimmune Enteropathy) typically involves autoantibodies or systemic autoimmunity, not mentioned; D (CVID) often presents with infections and hypogammaglobulinemia, unspecified; E (Tropical Sprue) implies travel to endemic areas, not indicated. Main medical accuracy issue(s): None; aligns with established knowledge that olmesartan can cause sprue-like enteropathy mimicking celiac, per guidelines and literature (e.g., FDA warnings). Item is clinically realistic and board-relevant. Minimal fix: No fix required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-002", "question": "A 34-year-old female with a history of oral contraceptive use presents with right upper quadrant pain. MRI of the liver reveals a 6 cm solitary lesion in segment V. The lesion is hyperintense on T2-weighted images, shows strong arterial enhancement, and retains contrast on the hepatobiliary phase of Eovist (gadoxetate) MRI. Biopsy shows hepatocytes with glutamine synthetase diffuse strong positivity. What is the most appropriate management?", "options": ["Discontinue oral contraceptives and surveillance imaging in 6 months", "Surgical resection", "Radiofrequency ablation", "Liver transplantation evaluation", "Reassurance and discharge"], "answer": "B", "answer_index": 1, "explanation": "The imaging and staining pattern (diffuse glutamine synthetase positivity) are diagnostic of a beta-catenin activated hepatocellular adenoma. Unlike HNF1A-inactivated or inflammatory adenomas, beta-catenin activated adenomas have a very high risk of malignant transformation to hepatocellular carcinoma (HCC) and do not regress significantly with OCP cessation. Resection is mandated regardless of size or symptoms.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include history of oral contraceptive use, right upper quadrant pain, 6 cm solitary liver lesion in segment V, MRI showing T2 hyperintensity, strong arterial enhancement, and contrast retention on hepatobiliary phase with Eovist, plus biopsy revealing diffuse strong glutamine synthetase positivity. These findings point to beta-catenin activated hepatocellular adenoma (HCA), known for high malignant transformation risk to hepatocellular carcinoma (HCC), distinguishing it from other HCA subtypes that may regress with OCP cessation. The stem supports surgical resection (B) as the best management due to this risk, regardless of size or symptoms. Alternatives are inferior: A assumes regression possible in non-beta-catenin types; C (ablation) is less definitive for potential malignancy; D (transplant) is overly aggressive without cirrhosis or multifocality; E ignores the high-risk features. No main logical issues; the item is coherent, with options permitting clear discrimination of a single best answer. No main medical accuracy issues; aligns with current guidelines (e.g., EASL) recommending resection for beta-catenin activated HCAs due to ~50% HCC risk. Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include history of oral contraceptive use, right upper quadrant pain, 6 cm solitary liver lesion in segment V, MRI showing T2 hyperintensity, strong arterial enhancement, and contrast retention on hepatobiliary phase with Eovist, plus biopsy revealing diffuse strong glutamine synthetase positivity. These findings point to beta-catenin activated hepatocellular adenoma (HCA), known for high malignant transformation risk to hepatocellular carcinoma (HCC), distinguishing it from other HCA subtypes that may regress with OCP cessation. The stem supports surgical resection (B) as the best management due to this risk, regardless of size or symptoms. Alternatives are inferior: A assumes regression possible in non-beta-catenin types; C (ablation) is less definitive for potential malignancy; D (transplant) is overly aggressive without cirrhosis or multifocality; E ignores the high-risk features. No main logical issues; the item is coherent, with options permitting clear discrimination of a single best answer. No main medical accuracy issues; aligns with current guidelines (e.g., EASL) recommending resection for beta-catenin activated HCAs due to ~50% HCC risk. Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-003", "question": "A 24-year-old female presents with menorrhagia and prolonged bleeding after a tooth extraction. Coagulation profile shows a prolonged aPTT (55s) and normal PT. Factor VIII activity is 6% (low). von Willebrand Factor (vWF) Antigen is 95% (normal), and vWF Ristocetin Cofactor Activity is 92% (normal). A mixing study corrects the aPTT. Her father has a similar bleeding history, but her brothers are unaffected. What is the most likely diagnosis?", "options": ["Hemophilia A (Carrier state)", "Type 2N von Willebrand Disease", "Type 2A von Willebrand Disease", "Acquired Hemophilia A", "Factor XI Deficiency"], "answer": "B", "answer_index": 1, "explanation": "Type 2N (Normandy) vWD is caused by a defect in the vWF binding domain for Factor VIII, leading to a secondary deficiency of Factor VIII (due to short half-life) despite normal vWF levels and function. It mimics Hemophilia A but exhibits autosomal recessive inheritance (affecting females significantly), whereas Hemophilia A is X-linked. The normal vWF antigen and activity rule out Type 1 and 2A/2B/2M.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 24-year-old female with menorrhagia and post-extraction bleeding; prolonged aPTT (55s) with normal PT; low Factor VIII (6%); normal vWF antigen (95%) and ristocetin cofactor (92%); mixing study corrects aPTT; father affected, brothers unaffected. These point to a Factor VIII deficiency with normal vWF, mimicking Hemophilia A but with autosomal inheritance pattern suggested by affected female and father.\\nMain logical issue(s), if any: None; stem provides sufficient discriminating details (low Factor VIII, normal vWF parameters, correction on mixing) to identify Type 2N vWD as unique best, ruling out alternatives like Hemophilia A carrier (typically ~50% Factor VIII, X-linked), Type 2A (low ristocetin activity), acquired (inhibitor unlikely with correction), and Factor XI (normal Factor VIII expected).\\nMain medical accuracy issue(s), if any: None; aligns with standard knowledge that Type 2N vWD causes secondary Factor VIII deficiency due to impaired vWF-Factor VIII binding, with autosomal recessive inheritance, distinguishing it from X-linked Hemophilia A.\\nMinimal fix: No edit needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 24-year-old female with menorrhagia and post-extraction bleeding; prolonged aPTT (55s) with normal PT; low Factor VIII (6%); normal vWF antigen (95%) and ristocetin cofactor (92%); mixing study corrects aPTT; father affected, brothers unaffected. These point to a Factor VIII deficiency with normal vWF, mimicking Hemophilia A but with autosomal inheritance pattern suggested by affected female and father.\nMain logical issue(s), if any: None; stem provides sufficient discriminating details (low Factor VIII, normal vWF parameters, correction on mixing) to identify Type 2N vWD as unique best, ruling out alternatives like Hemophilia A carrier (typically ~50% Factor VIII, X-linked), Type 2A (low ristocetin activity), acquired (inhibitor unlikely with correction), and Factor XI (normal Factor VIII expected).\nMain medical accuracy issue(s), if any: None; aligns with standard knowledge that Type 2N vWD causes secondary Factor VIII deficiency due to impaired vWF-Factor VIII binding, with autosomal recessive inheritance, distinguishing it from X-linked Hemophilia A.\nMinimal fix: No edit needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-004", "question": "A 19-year-old male presents with recurrent fevers, livedo reticularis, and two episodes of lacunar ischemic stroke. Laboratory evaluation reveals low serum IgM and IgG levels, mild neutropenia, and elevated inflammatory markers. A biopsy of a skin nodule shows necrotizing vasculitis. Genetic testing is most likely to reveal a loss-of-function mutation in which gene?", "options": ["MEFV", "ADA2", "NOD2", "TNFRSF1A", "STAT3"], "answer": "B", "answer_index": 1, "explanation": "This clinical presentation is classic for Deficiency of Adenosine Deaminase 2 (DADA2). It presents with a polyarteritis nodosa (PAN)-like vasculitis, early-onset strokes, and mild immunodeficiency (hypogammaglobulinemia/cytopenias). It is an autosomal recessive autoinflammatory disease. MEFV causes Familial Mediterranean Fever; STAT3 causes Hyper-IgE syndrome.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Recurrent fevers, livedo reticularis, lacunar ischemic strokes in a young adult, low IgM/IgG with mild neutropenia, elevated inflammatory markers, and skin biopsy showing necrotizing vasculitis—all hallmark of DADA2 (ADA2 deficiency), an autoinflammatory vasculitis with immunodeficiency and early strokes. These discriminate against other autoinflammatory genes.\\nMain logical issue(s), if any: None; stem provides sufficient details for a single best answer without contradictions or underspecification, allowing clear discrimination among options.\\nMain medical accuracy issue(s), if any: None; presentation aligns with current consensus on DADA2 (e.g., PAN-like vasculitis, hypogammaglobulinemia, cytopenias, strokes per major guidelines like those from NIH and rheumatology literature). Alternatives are appropriately incorrect: MEFV (FMF: serositis, no strokes); NOD2 (Blau: granulomas); TNFRSF1A (TRAPS: periodic fevers, no immunodeficiency); STAT3 (Hyper-IgE: high IgE, infections).\\nMinimal fix: No edit needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Recurrent fevers, livedo reticularis, lacunar ischemic strokes in a young adult, low IgM/IgG with mild neutropenia, elevated inflammatory markers, and skin biopsy showing necrotizing vasculitis—all hallmark of DADA2 (ADA2 deficiency), an autoinflammatory vasculitis with immunodeficiency and early strokes. These discriminate against other autoinflammatory genes.\nMain logical issue(s), if any: None; stem provides sufficient details for a single best answer without contradictions or underspecification, allowing clear discrimination among options.\nMain medical accuracy issue(s), if any: None; presentation aligns with current consensus on DADA2 (e.g., PAN-like vasculitis, hypogammaglobulinemia, cytopenias, strokes per major guidelines like those from NIH and rheumatology literature). Alternatives are appropriately incorrect: MEFV (FMF: serositis, no strokes); NOD2 (Blau: granulomas); TNFRSF1A (TRAPS: periodic fevers, no immunodeficiency); STAT3 (Hyper-IgE: high IgE, infections).\nMinimal fix: No edit needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-005", "question": "A 65-year-old male with metastatic colorectal cancer is being evaluated for third-line therapy. Molecular profiling reveals the tumor is KRAS wild-type, NRAS wild-type, and BRAF V600E mutated. Microsatellite status is stable (MSS). Which of the following regimens is the most appropriate targeted therapy?", "options": ["Vemurafenib monotherapy", "Encorafenib plus Cetuximab", "Dabrafenib plus Trametinib", "Pembrolizumab monotherapy", "Regorafenib monotherapy"], "answer": "B", "answer_index": 1, "explanation": "In BRAF V600E-mutated colorectal cancer, BRAF inhibitor monotherapy (e.g., Vemurafenib) is ineffective due to a feedback loop that causes rapid upregulation of EGFR signaling. The standard of care, based on the BEACON trial, is the combination of a BRAF inhibitor (Encorafenib) and an EGFR inhibitor (Cetuximab) to block this feedback loop. Pembrolizumab is only for MSI-High tumors.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 65-year-old male with metastatic colorectal cancer (mCRC) in third-line setting; tumor profiling shows KRAS wild-type, NRAS wild-type, BRAF V600E mutated, and microsatellite stable (MSS). These findings imply need for targeted therapy addressing BRAF V600E mutation in MSS mCRC, where BRAF inhibitor monotherapy fails due to EGFR feedback, but combination BRAF + EGFR inhibition is supported by BEACON CRC trial. Keyed answer B (Encorafenib plus Cetuximab) fits as the standard of care. Alternatives: A (Vemurafenib monotherapy) ineffective per trial data; C (Dabrafenib plus Trametinib) standard for BRAF-mutated melanoma but not CRC due to differing resistance mechanisms; D (Pembrolizumab monotherapy) indicated only for MSI-high tumors, not MSS; E (Regorafenib monotherapy) is a multikinase inhibitor for refractory mCRC but not specifically targeted to BRAF V600E and less effective than combination therapy. No main logical issues; stem allows discrimination of single best option without contradictions or underspecification. No main medical accuracy issues; aligns with NCCN guidelines and BEACON trial results, representing current mainstream standards without inaccuracies or outdated guidance. Minimal fix: None needed, as item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 65-year-old male with metastatic colorectal cancer (mCRC) in third-line setting; tumor profiling shows KRAS wild-type, NRAS wild-type, BRAF V600E mutated, and microsatellite stable (MSS). These findings imply need for targeted therapy addressing BRAF V600E mutation in MSS mCRC, where BRAF inhibitor monotherapy fails due to EGFR feedback, but combination BRAF + EGFR inhibition is supported by BEACON CRC trial. Keyed answer B (Encorafenib plus Cetuximab) fits as the standard of care. Alternatives: A (Vemurafenib monotherapy) ineffective per trial data; C (Dabrafenib plus Trametinib) standard for BRAF-mutated melanoma but not CRC due to differing resistance mechanisms; D (Pembrolizumab monotherapy) indicated only for MSI-high tumors, not MSS; E (Regorafenib monotherapy) is a multikinase inhibitor for refractory mCRC but not specifically targeted to BRAF V600E and less effective than combination therapy. No main logical issues; stem allows discrimination of single best option without contradictions or underspecification. No main medical accuracy issues; aligns with NCCN guidelines and BEACON trial results, representing current mainstream standards without inaccuracies or outdated guidance. Minimal fix: None needed, as item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-006", "question": "A 45-year-old male presents with recurrent episodes of hypotension and syncope occurring 3 to 6 hours after eating dinner. He has no history of atopy. Skin prick tests to beef, pork, and lamb are negative, but intradermal testing is positive. Serum tryptase is normal. Specific IgE testing reveals elevated IgE to galactose-alpha-1,3-galactose. Which of the following is the most likely vector for sensitization in this patient?", "options": ["Ixodes scapularis (Black-legged tick)", "Amblyomma americanum (Lone Star tick)", "Dermacentor variabilis (American Dog tick)", "Aedes aegypti (Mosquito)", "Ctenocephalides felis (Cat flea)"], "answer": "B", "answer_index": 1, "explanation": "This is Alpha-gal syndrome, a delayed anaphylactic reaction to mammalian meat (red meat) mediated by IgE against the alpha-gal carbohydrate. Sensitization is caused by bites from the Lone Star tick (*Amblyomma americanum*) in the US. The reaction is characteristically delayed (3-6 hours) unlike typical protein-based food allergies.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent hypotension and syncope 3-6 hours post-dinner (delayed reaction), no atopy, negative skin prick but positive intradermal to meats, normal tryptase, and elevated IgE to galactose-alpha-1,3-galactose (alpha-gal), pointing to alpha-gal syndrome from tick sensitization. The clinical problem asks for the most likely vector causing alpha-gal IgE sensitization leading to delayed red meat allergy. Discriminating findings: delayed onset after mammalian meat ingestion, specific IgE elevation. Most likely mechanism: tick bite introducing alpha-gal. Keyed answer B (Amblyomma americanum) fits as the primary US vector for alpha-gal sensitization, with no assumptions needed. Alternatives: A (Ixodes scapularis) associated with Lyme, not alpha-gal; C (Dermacentor variabilis) linked to spotted fever, not alpha-gal; D (Aedes aegypti) mosquito, no alpha-gal link; E (Ctenocephalides felis) flea, irrelevant. No main logical issues; stem is consistent, supports unique best answer without contradictions or underspecification. No main medical accuracy issues; aligns with current guidelines on alpha-gal syndrome, where Lone Star tick is the established sensitizer, with accurate pathophysiology and testing details. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent hypotension and syncope 3-6 hours post-dinner (delayed reaction), no atopy, negative skin prick but positive intradermal to meats, normal tryptase, and elevated IgE to galactose-alpha-1,3-galactose (alpha-gal), pointing to alpha-gal syndrome from tick sensitization. The clinical problem asks for the most likely vector causing alpha-gal IgE sensitization leading to delayed red meat allergy. Discriminating findings: delayed onset after mammalian meat ingestion, specific IgE elevation. Most likely mechanism: tick bite introducing alpha-gal. Keyed answer B (Amblyomma americanum) fits as the primary US vector for alpha-gal sensitization, with no assumptions needed. Alternatives: A (Ixodes scapularis) associated with Lyme, not alpha-gal; C (Dermacentor variabilis) linked to spotted fever, not alpha-gal; D (Aedes aegypti) mosquito, no alpha-gal link; E (Ctenocephalides felis) flea, irrelevant. No main logical issues; stem is consistent, supports unique best answer without contradictions or underspecification. No main medical accuracy issues; aligns with current guidelines on alpha-gal syndrome, where Lone Star tick is the established sensitizer, with accurate pathophysiology and testing details. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-007", "question": "A 78-year-old female is evaluated for progressive visual dysfunction. She reports difficulty reading and navigating her home, often bumping into doorframes. Her family notes she cannot reach for objects accurately (optic ataxia) and cannot describe the entire scene of a picture (simultanagnosia). Memory and language are relatively preserved. MRI shows predominant atrophy of the parietal and occipital lobes. What is the most likely underlying pathology?", "options": ["Lewy Body Disease", "Prion Disease (CJD)", "Alzheimer's Disease pathology (Amyloid plaques/Tau tangles)", "Frontotemporal Lobar Degeneration (TDP-43)", "Vascular Dementia"], "answer": "C", "answer_index": 2, "explanation": "This patient presents with Posterior Cortical Atrophy (PCA), also known as Benson's syndrome. The clinical hallmark is Balint's syndrome (simultanagnosia, optic ataxia, oculomotor apraxia) and Gerstmann's syndrome. Despite the atypical visual presentation, the underlying pathology in the vast majority (>80%) of PCA cases is Alzheimer's disease (amyloid plaques and neurofibrillary tangles).", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive visual dysfunction with optic ataxia and simultanagnosia (elements of Balint's syndrome), preserved memory and language, and MRI showing predominant parietal and occipital lobe atrophy, collectively pointing to posterior cortical atrophy (PCA) syndrome. The question asks for the most likely underlying pathology, and mainstream medical consensus (e.g., Alzheimer's Association guidelines) indicates that >80% of PCA cases are due to Alzheimer's disease pathology (amyloid plaques and tau tangles), making C the single best option. Main logical issues: none; the stem provides sufficient discriminating findings without contradictions or underspecification, allowing clear differentiation from alternatives like Lewy body disease (A, which typically involves hallucinations and parkinsonism, not this focal visuospatial deficit), prion disease (B, rapid progression without this atrophy pattern), frontotemporal lobar degeneration (D, frontal/temporal predominance), and vascular dementia (E, expected vascular lesions on imaging). Main medical accuracy issues: none; the item's teaching point aligns with current standards, accurately associating PCA with AD pathology without outdated or erroneous elements. Minimal fix: none required, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include progressive visual dysfunction with optic ataxia and simultanagnosia (elements of Balint's syndrome), preserved memory and language, and MRI showing predominant parietal and occipital lobe atrophy, collectively pointing to posterior cortical atrophy (PCA) syndrome. The question asks for the most likely underlying pathology, and mainstream medical consensus (e.g., Alzheimer's Association guidelines) indicates that >80% of PCA cases are due to Alzheimer's disease pathology (amyloid plaques and tau tangles), making C the single best option. Main logical issues: none; the stem provides sufficient discriminating findings without contradictions or underspecification, allowing clear differentiation from alternatives like Lewy body disease (A, which typically involves hallucinations and parkinsonism, not this focal visuospatial deficit), prion disease (B, rapid progression without this atrophy pattern), frontotemporal lobar degeneration (D, frontal/temporal predominance), and vascular dementia (E, expected vascular lesions on imaging). Main medical accuracy issues: none; the item's teaching point aligns with current standards, accurately associating PCA with AD pathology without outdated or erroneous elements. Minimal fix: none required, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-008", "question": "A 28-year-old male with ulcerative colitis is admitted with jaundice and pruritus. MRCP shows multifocal strictures and dilations of the intrahepatic and extrahepatic bile ducts. IgG4 levels are 2x upper limit of normal. A liver biopsy shows periductal concentric fibrosis ('onion-skinning') without abundant plasma cells. A trial of high-dose corticosteroids results in no biochemical improvement. What is the diagnosis?", "options": ["IgG4-related Sclerosing Cholangitis", "Primary Sclerosing Cholangitis (PSC)", "Cholangiocarcinoma", "Secondary Sclerosing Cholangitis", "Autoimmune Hepatitis overlap syndrome"], "answer": "B", "answer_index": 1, "explanation": "This is classic Primary Sclerosing Cholangitis (PSC) associated with IBD. While IgG4 can be elevated in PSC (up to 15% of cases), the lack of response to steroids and the classic 'onion-skin' fibrosis distinguish it from IgG4-related Sclerosing Cholangitis (IgG4-SC). IgG4-SC typically responds dramatically to steroids and shows abundant IgG4+ plasma cells on biopsy.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include association with ulcerative colitis (strong PSC link), MRCP showing multifocal strictures and dilations (classic 'beads-on-a-string' for PSC), mildly elevated IgG4 (2x ULN, possible in 10-15% of PSC but not diagnostic of IgG4-SC), liver biopsy with periductal 'onion-skin' fibrosis without abundant plasma cells (hallmark of PSC, contrasts with IgG4-SC's lymphoplasmacytic infiltrate), and lack of response to high-dose corticosteroids (PSC is steroid-refractory, while IgG4-SC typically shows dramatic improvement). These clues collectively point to PSC as the single best diagnosis, excluding alternatives. Main logical issue(s): None; the stem provides sufficient discriminating details without contradictions or underspecification, allowing clear differentiation. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., AASLD on PSC diagnosis, differentiation from IgG4-SC via biopsy and steroid response). The item's teaching point on distinguishing PSC from IgG4-SC is precise and board-relevant, noting mild IgG4 elevation in PSC without implying it's exclusionary. Minimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include association with ulcerative colitis (strong PSC link), MRCP showing multifocal strictures and dilations (classic 'beads-on-a-string' for PSC), mildly elevated IgG4 (2x ULN, possible in 10-15% of PSC but not diagnostic of IgG4-SC), liver biopsy with periductal 'onion-skin' fibrosis without abundant plasma cells (hallmark of PSC, contrasts with IgG4-SC's lymphoplasmacytic infiltrate), and lack of response to high-dose corticosteroids (PSC is steroid-refractory, while IgG4-SC typically shows dramatic improvement). These clues collectively point to PSC as the single best diagnosis, excluding alternatives. Main logical issue(s): None; the stem provides sufficient discriminating details without contradictions or underspecification, allowing clear differentiation. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., AASLD on PSC diagnosis, differentiation from IgG4-SC via biopsy and steroid response). The item's teaching point on distinguishing PSC from IgG4-SC is precise and board-relevant, noting mild IgG4 elevation in PSC without implying it's exclusionary. Minimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-009", "question": "A 60-year-old female undergoes surveillance colonoscopy. A 15mm flat lesion is removed from the ascending colon. Pathology reveals a Sessile Serrated Lesion (SSL) with dysplasia. According to the 2020 US Multi-Society Task Force guidelines, when should her next surveillance colonoscopy be performed?", "options": ["1 year", "3 years", "5 years", "7 years", "10 years"], "answer": "B", "answer_index": 1, "explanation": "Sessile Serrated Lesions (SSLs) with dysplasia are considered high-risk precancerous lesions, equivalent in risk to high-risk adenomas (e.g., villous histology, high-grade dysplasia, or size >10mm). The recommended surveillance interval for an SSL with dysplasia (regardless of size) is 3 years. An SSL <10mm without dysplasia would be 5-10 years.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's age (60 years), a 15mm flat lesion in the ascending colon identified as a Sessile Serrated Lesion (SSL) with dysplasia on pathology, and the query specifying the 2020 US Multi-Society Task Force guidelines for surveillance colonoscopy timing. These clues point to SSL with dysplasia as a high-risk precancerous lesion, equivalent to high-risk adenomas (e.g., size >10mm or high-grade dysplasia), warranting a 3-year interval. No main logical issues; the stem is internally consistent, supports a single best answer (B, 3 years), and the key matches it without requiring unstated assumptions. Options are well-differentiated: A (1 year) is overly aggressive, typically for malignancy or incomplete resection; C (5 years) suits low-risk serrated polyps without dysplasia; D (7 years) and E (10 years) align with even lower risk or normal findings. No main medical accuracy issues; the item's logic aligns with 2020 USMSTF guidelines, which recommend 3 years for SSLs with dysplasia regardless of size, reflecting current mainstream standards without inaccuracies, outdated guidance, or regional variations affecting the best answer. Minimal fix: None required, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's age (60 years), a 15mm flat lesion in the ascending colon identified as a Sessile Serrated Lesion (SSL) with dysplasia on pathology, and the query specifying the 2020 US Multi-Society Task Force guidelines for surveillance colonoscopy timing. These clues point to SSL with dysplasia as a high-risk precancerous lesion, equivalent to high-risk adenomas (e.g., size >10mm or high-grade dysplasia), warranting a 3-year interval. No main logical issues; the stem is internally consistent, supports a single best answer (B, 3 years), and the key matches it without requiring unstated assumptions. Options are well-differentiated: A (1 year) is overly aggressive, typically for malignancy or incomplete resection; C (5 years) suits low-risk serrated polyps without dysplasia; D (7 years) and E (10 years) align with even lower risk or normal findings. No main medical accuracy issues; the item's logic aligns with 2020 USMSTF guidelines, which recommend 3 years for SSLs with dysplasia regardless of size, reflecting current mainstream standards without inaccuracies, outdated guidance, or regional variations affecting the best answer. Minimal fix: None required, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-010", "question": "A 55-year-old male with AL amyloidosis presents with extensive ecchymoses and a large hematoma after a minor venipuncture. Coagulation studies reveal a PT of 18s (Normal 11-13.5) and a PTT of 45s (Normal 25-35). Thrombin time is normal. Mixing studies correct both PT and PTT. Factor assays reveal Factor X activity of 8%. What is the mechanism of this deficiency?", "options": ["Autoantibody inhibition of Factor X", "Adsorption of Factor X onto amyloid fibrils", "Decreased hepatic synthesis of Factor X", "Urinary loss of Factor X due to nephrotic syndrome", "Consumption due to low-grade DIC"], "answer": "B", "answer_index": 1, "explanation": "Acquired Factor X deficiency is a rare but classic complication of AL amyloidosis (occurring in ~8-10% of patients). The mechanism is the adsorption (binding) of Factor X to the amyloid fibrils in the spleen and liver, removing it from circulation. It is not an inhibitor (antibody) or synthesis issue. Treatment often requires splenectomy or high-dose factor replacement to overwhelm the binding sites.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: AL amyloidosis diagnosis, bleeding diathesis with ecchymoses and hematoma post-venipuncture, prolonged PT (18s) and PTT (45s) with normal thrombin time, mixing studies correcting both, and isolated Factor X activity at 8%. These point to an acquired, non-inhibitor Factor X deficiency specific to amyloidosis, favoring adsorption onto amyloid fibrils (B) as the mechanism. Main logical issue(s), if any: None; the vignette provides sufficient details to discriminate B as uniquely best, with no contradictions or underspecification—mixing studies rule out inhibitors (A), normal thrombin time excludes DIC (E), no mention of liver failure for synthesis defect (C) or nephrotic syndrome for urinary loss (D). Main medical accuracy issue(s), if any: None; aligns with established knowledge that AL amyloidosis can cause selective Factor X deficiency via adsorption to amyloid deposits in spleen/liver, not autoantibodies or other mechanisms. This is consistent with current hematology guidelines and board-level teaching. Minimal fix: Not needed, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: AL amyloidosis diagnosis, bleeding diathesis with ecchymoses and hematoma post-venipuncture, prolonged PT (18s) and PTT (45s) with normal thrombin time, mixing studies correcting both, and isolated Factor X activity at 8%. These point to an acquired, non-inhibitor Factor X deficiency specific to amyloidosis, favoring adsorption onto amyloid fibrils (B) as the mechanism. Main logical issue(s), if any: None; the vignette provides sufficient details to discriminate B as uniquely best, with no contradictions or underspecification—mixing studies rule out inhibitors (A), normal thrombin time excludes DIC (E), no mention of liver failure for synthesis defect (C) or nephrotic syndrome for urinary loss (D). Main medical accuracy issue(s), if any: None; aligns with established knowledge that AL amyloidosis can cause selective Factor X deficiency via adsorption to amyloid deposits in spleen/liver, not autoantibodies or other mechanisms. This is consistent with current hematology guidelines and board-level teaching. Minimal fix: Not needed, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-011", "question": "A 30-year-old female presents with recurrent sinopulmonary infections and splenomegaly. Labs show low IgG, low IgA, and variable IgM. She is diagnosed with Common Variable Immunodeficiency (CVID). Five years later, she develops progressive dyspnea. CT chest shows diffuse pulmonary nodules and mediastinal lymphadenopathy. Biopsy reveals non-necrotizing granulomas. Stains for fungi and mycobacteria are negative. What is the preferred initial treatment for this complication?", "options": ["Infliximab", "Rituximab and Azathioprine/Mycophenolate", "High-dose Intravenous Immunoglobulin (IVIG) alone", "Lung Transplantation", "Antituberculous therapy"], "answer": "B", "answer_index": 1, "explanation": "The patient has Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD), a distinct and serious complication of CVID. Unlike sarcoidosis, GLILD in CVID is driven by B-cell hyperplasia and T-cell dysregulation. The consensus treatment for progressive GLILD is combination immunosuppression, typically Rituximab (to deplete B cells) combined with an antimetabolite like Azathioprine or Mycophenolate. IVIG alone is insufficient for GLILD.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Recurrent sinopulmonary infections, splenomegaly, low IgG/IgA with variable IgM confirming CVID; later progressive dyspnea with CT showing diffuse pulmonary nodules and mediastinal lymphadenopathy; biopsy revealing non-necrotizing granulomas with negative fungal/mycobacterial stains. These point to GLILD as the complication, a known CVID-associated interstitial lung disease driven by immune dysregulation.\\nMain logical issue(s), if any: None; the vignette provides sufficient discriminating details (e.g., negative stains rule out infection, granulomas suggest GLILD over other CVID lung issues) to identify a single best initial treatment without contradictions or underspecification.\\nMain medical accuracy issue(s), if any: None; aligns with current consensus on GLILD management in CVID, where rituximab plus azathioprine/mycophenolate targets B-cell and T-cell dysregulation, superior to IVIG alone or other options for progressive cases. Infliximab is more for sarcoidosis; transplantation is not initial; antituberculous therapy inappropriate given negative stains.\\nMinimal fix: No fix required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Recurrent sinopulmonary infections, splenomegaly, low IgG/IgA with variable IgM confirming CVID; later progressive dyspnea with CT showing diffuse pulmonary nodules and mediastinal lymphadenopathy; biopsy revealing non-necrotizing granulomas with negative fungal/mycobacterial stains. These point to GLILD as the complication, a known CVID-associated interstitial lung disease driven by immune dysregulation.\nMain logical issue(s), if any: None; the vignette provides sufficient discriminating details (e.g., negative stains rule out infection, granulomas suggest GLILD over other CVID lung issues) to identify a single best initial treatment without contradictions or underspecification.\nMain medical accuracy issue(s), if any: None; aligns with current consensus on GLILD management in CVID, where rituximab plus azathioprine/mycophenolate targets B-cell and T-cell dysregulation, superior to IVIG alone or other options for progressive cases. Infliximab is more for sarcoidosis; transplantation is not initial; antituberculous therapy inappropriate given negative stains.\nMinimal fix: No fix required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-012", "question": "A 62-year-old male with metastatic melanoma is treated with Ipilimumab and Nivolumab. Four weeks after the second cycle, he presents with fatigue, nausea, and hypotension. Labs show Sodium 130 mEq/L, Potassium 5.2 mEq/L, Glucose 65 mg/dL. TSH is 0.05 mIU/L (Low), Free T4 is 0.6 ng/dL (Low). ACTH is <5 pg/mL. MRI brain shows enlargement of the pituitary gland. What is the diagnosis?", "options": ["Primary Adrenal Insufficiency (Addison's)", "Immune Checkpoint Inhibitor-induced Hypophysitis", "Thyroid Storm", "Pituitary Metastasis", "Syndrome of Inappropriate ADH (SIADH)"], "answer": "B", "answer_index": 1, "explanation": "This is a classic presentation of hypophysitis (inflammation of the pituitary), a specific immune-related adverse event (irAE) strongly associated with CTLA-4 inhibitors (Ipilimumab). The key biochemical pattern is central hypothyroidism (Low TSH, Low T4) and central adrenal insufficiency (Low ACTH, Low Cortisol, hyponatremia/hyperkalemia). Primary adrenal insufficiency would have high ACTH. The MRI finding confirms pituitary inflammation.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include treatment with Ipilimumab and Nivolumab for metastatic melanoma, presentation with fatigue, nausea, hypotension after second cycle, labs showing hyponatremia (130 mEq/L), hyperkalemia (5.2 mEq/L), hypoglycemia (65 mg/dL), low TSH (0.05 mIU/L) and free T4 (0.6 ng/dL) indicating central hypothyroidism, low ACTH (<5 pg/mL) suggesting central adrenal insufficiency, and MRI revealing pituitary enlargement. These findings strongly point to immune checkpoint inhibitor-induced hypophysitis, a known irAE particularly with CTLA-4 inhibitors like Ipilimumab. Main logical issues: none; the stem provides sufficient discriminating details to identify B as the unique best answer without contradictions or underspecification. Alternatives are inferior: A (primary adrenal insufficiency) would show high ACTH; C (thyroid storm) involves hyperthyroidism, not hypo; D (pituitary metastasis) is possible but less likely given the irAE context and lack of other metastatic evidence; E (SIADH) explains hyponatremia but not hyperkalemia, adrenal, or thyroid findings. Main medical accuracy issues: none; aligns with current guidelines on checkpoint inhibitor toxicities, including central endocrinopathies and hypophysitis presentation per NCCN and ASCO standards. Minimal fix: none needed, as the item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include treatment with Ipilimumab and Nivolumab for metastatic melanoma, presentation with fatigue, nausea, hypotension after second cycle, labs showing hyponatremia (130 mEq/L), hyperkalemia (5.2 mEq/L), hypoglycemia (65 mg/dL), low TSH (0.05 mIU/L) and free T4 (0.6 ng/dL) indicating central hypothyroidism, low ACTH (<5 pg/mL) suggesting central adrenal insufficiency, and MRI revealing pituitary enlargement. These findings strongly point to immune checkpoint inhibitor-induced hypophysitis, a known irAE particularly with CTLA-4 inhibitors like Ipilimumab. Main logical issues: none; the stem provides sufficient discriminating details to identify B as the unique best answer without contradictions or underspecification. Alternatives are inferior: A (primary adrenal insufficiency) would show high ACTH; C (thyroid storm) involves hyperthyroidism, not hypo; D (pituitary metastasis) is possible but less likely given the irAE context and lack of other metastatic evidence; E (SIADH) explains hyponatremia but not hyperkalemia, adrenal, or thyroid findings. Main medical accuracy issues: none; aligns with current guidelines on checkpoint inhibitor toxicities, including central endocrinopathies and hypophysitis presentation per NCCN and ASCO standards. Minimal fix: none needed, as the item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-013", "question": "A 22-year-old female presents with recurrent episodes of abdominal pain and extremity swelling lasting 2-3 days. She has no urticaria during these episodes. Her C4 level is consistently low. C1-Inhibitor (C1-INH) quantitative level is 8 mg/dL (Normal 19-37) and C1-INH functional activity is 15% (Normal >68%). Which of the following is the most appropriate long-term prophylactic therapy?", "options": ["Antihistamines (Cetirizine)", "Omalizumab", "Danazol or Lanadelumab", "Systemic Corticosteroids", "Epinephrine auto-injector"], "answer": "C", "answer_index": 2, "explanation": "The patient has Hereditary Angioedema (HAE) Type 1 (low C1-INH level and function). HAE is bradykinin-mediated, not histamine-mediated; therefore, antihistamines, corticosteroids, and epinephrine are ineffective. Long-term prophylaxis is indicated for frequent attacks. Options include attenuated androgens (Danazol) or modern agents like Lanadelumab (kallikrein inhibitor) or Berotralstat. C1-INH replacement is also used.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 22-year-old female with recurrent abdominal pain and extremity swelling lasting 2-3 days, no urticaria, consistently low C4, C1-INH quantitative 8 mg/dL (normal 19-37), functional activity 15% (normal >68%). These drive a unique best answer by indicating hereditary angioedema (HAE) Type 1, a bradykinin-mediated condition requiring specific prophylaxis like attenuated androgens (Danazol) or kallikrein inhibitors (Lanadelumab), matching option C. Alternatives are inferior: A (antihistamines) and D (corticosteroids) target histamine pathways ineffective in HAE; E (epinephrine) is for anaphylaxis; B (omalizumab) is for IgE-mediated urticaria, not HAE. No main logical issues; stem allows discrimination of one best option without contradictions or underspecification, though attack frequency is not quantified, it implies need for prophylaxis via question phrasing. Main medical accuracy issues: None; aligns with current guidelines (e.g., US Hereditary Angioedema Association) for HAE prophylaxis in patients with recurrent attacks, distinguishing from allergic angioedema. Minimal fix: No fix required, but adding 'with attacks occurring monthly' to stem would enhance clarity on prophylaxis indication without altering intent.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 22-year-old female with recurrent abdominal pain and extremity swelling lasting 2-3 days, no urticaria, consistently low C4, C1-INH quantitative 8 mg/dL (normal 19-37), functional activity 15% (normal >68%). These drive a unique best answer by indicating hereditary angioedema (HAE) Type 1, a bradykinin-mediated condition requiring specific prophylaxis like attenuated androgens (Danazol) or kallikrein inhibitors (Lanadelumab), matching option C. Alternatives are inferior: A (antihistamines) and D (corticosteroids) target histamine pathways ineffective in HAE; E (epinephrine) is for anaphylaxis; B (omalizumab) is for IgE-mediated urticaria, not HAE. No main logical issues; stem allows discrimination of one best option without contradictions or underspecification, though attack frequency is not quantified, it implies need for prophylaxis via question phrasing. Main medical accuracy issues: None; aligns with current guidelines (e.g., US Hereditary Angioedema Association) for HAE prophylaxis in patients with recurrent attacks, distinguishing from allergic angioedema. Minimal fix: No fix required, but adding 'with attacks occurring monthly' to stem would enhance clarity on prophylaxis indication without altering intent.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed130", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed130-014", "question": "A 72-year-old male is evaluated for frequent falls. He reports that his legs feel 'heavy' and 'stuck to the floor' when he tries to start walking, but once moving, he can walk relatively well. He has urinary urgency and mild cognitive impairment. Physical exam reveals a broad-based, shuffling gait with difficulty lifting feet (magnetic gait). What is the most likely diagnosis?", "options": ["Parkinson's Disease", "Normal Pressure Hydrocephalus (NPH)", "Lumbar Spinal Stenosis", "Vascular Dementia", "Cerebellar Ataxia"], "answer": "B", "answer_index": 1, "explanation": "The clinical triad of gait disturbance, urinary incontinence (urgency), and dementia ('wobbly, wet, and wacky') suggests Normal Pressure Hydrocephalus (NPH). The specific description of a 'magnetic gait' (gait apraxia where feet appear stuck to the floor) is the hallmark and usually the earliest sign. It is distinguished from Parkinson's by the lack of resting tremor and the specific nature of the gait initiation failure.", "generator_model": "gemini-3-pro-preview", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the 72-year-old male's frequent falls, legs feeling 'heavy' and 'stuck to the floor' during gait initiation (magnetic gait), improvement once moving, urinary urgency, mild cognitive impairment, and broad-based shuffling gait. These form the classic triad of gait apraxia, urinary incontinence, and dementia, pointing uniquely to Normal Pressure Hydrocephalus (NPH) as the most likely diagnosis. Main logical issue(s): None; the vignette provides sufficient discriminating details without contradictions, allowing selection of one best option (B) while alternatives are less fitting—A (Parkinson's) lacks resting tremor and has different gait (festinating); C (Lumbar Spinal Stenosis) typically causes neurogenic claudication without cognitive or urinary symptoms; D (Vascular Dementia) may involve stepwise decline but not specific magnetic gait; E (Cerebellar Ataxia) features intention tremor and dysmetria absent here. Main medical accuracy issue(s): None; aligns with current standards, where NPH is characterized by the 'wobbly, wet, and wacky' triad, with magnetic gait as an early hallmark, distinguishing it from Parkinson's. The rationale correctly notes the absence of tremor. Minimal fix: None required; item is already unambiguous and accurate, though adding 'no resting tremor' to the stem could further emphasize distinction from Parkinson's if desired.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the 72-year-old male's frequent falls, legs feeling 'heavy' and 'stuck to the floor' during gait initiation (magnetic gait), improvement once moving, urinary urgency, mild cognitive impairment, and broad-based shuffling gait. These form the classic triad of gait apraxia, urinary incontinence, and dementia, pointing uniquely to Normal Pressure Hydrocephalus (NPH) as the most likely diagnosis. Main logical issue(s): None; the vignette provides sufficient discriminating details without contradictions, allowing selection of one best option (B) while alternatives are less fitting—A (Parkinson's) lacks resting tremor and has different gait (festinating); C (Lumbar Spinal Stenosis) typically causes neurogenic claudication without cognitive or urinary symptoms; D (Vascular Dementia) may involve stepwise decline but not specific magnetic gait; E (Cerebellar Ataxia) features intention tremor and dysmetria absent here. Main medical accuracy issue(s): None; aligns with current standards, where NPH is characterized by the 'wobbly, wet, and wacky' triad, with magnetic gait as an early hallmark, distinguishing it from Parkinson's. The rationale correctly notes the absence of tremor. Minimal fix: None required; item is already unambiguous and accurate, though adding 'no resting tremor' to the stem could further emphasize distinction from Parkinson's if desired.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]